Concord Drugs Limited reported a strong FY 2025-26, with standalone revenue doubling to Rs 75.85 crore and profit after tax rising significantly to Rs 1.04 crore. The company strengthened its balance sheet through a preferential allotment of shares and warrants while opting not to declare a dividend to preserve capital for growth. Shareholders should remain mindful of pending historical tax litigation and recent minor regulatory compliance issues noted in the annual report.
Concord Drugs Reports Strong FY 2025-26 Financials
Standalone Revenue: Rs 75.85 crore | Profit After Tax: Rs 1.04 crore
Reader Takeaway: Revenue and profit growth are robust, though ongoing income tax litigation remains a key area for monitoring.
What just happened
Concord Drugs Limited has filed its 31st Annual Report for FY 2025-26, showcasing a sharp increase in financial performance. Standalone revenue climbed to Rs 75.85 crore from Rs 36.93 crore in the previous year. Profit after tax also saw substantial growth, reaching Rs 1.04 crore compared to Rs 0.30 crore in FY 24-25. Basic EPS rose to Rs 0.93 from Rs 0.30.
Why this matters
The doubling of both top and bottom-line metrics signals improved operational efficiency. Additionally, the company successfully executed a preferential allotment of 31,75,000 equity shares and 20,25,000 convertible warrants at Rs 36.30 per unit. This capital infusion, alongside an increase in authorized share capital to Rs 15.5 crore, suggests management is positioning the company for expansion.
Corporate Actions
In line with a strategy to preserve liquidity for shareholder value improvement, the board decided not to recommend a dividend for FY 2025-26. The company also confirmed the re-appointment of its Managing Director, Mr. S. Nagi Reddy, and proposed the re-appointment of Statutory Auditors, M/s. Pundarikashyam and Associates.
Risks to watch
Investors should note potential headwinds, including pending income tax litigation of Rs 2.58 crore for A.Y. 2011-12. The case is currently being reviewed by the Assessing Officer following a remand by the ITAT. Furthermore, the company reported minor regulatory compliance issues, including a fine of Rs 2,00,600 paid to the BSE for non-compliance with LODR Regulation 6(1) and a reported delay in filing requirements.